10.1080/14017430601049449 60 ViechtbauerW
Long-term safety remains largely unknown due to limited research and regulation
In studies of GLP-1 RAs, used as a monotherapy or in combination with other glucose-lowering therapies, mean HbA 1c changes from baseline ranged from 0.2% to 1.9% ( 2.2 to 20.9 mmol/mol) (Fig
The once-weekly triple-hormone receptor agonist was generally well tolerated and provided substantial reductions in weight, as well as clinically meaningful improvements in health outcomes for patients with obesity, OSA, and knee OA, said Ania Jastreboff, MD, PhD, Professor at Yale University School and Director of the Y-Weight Obesity Research Center
Liver fat comparison This is where retatrutide separates from the competition most decisively
Future prospects Its tough to predict when many shortages may be resolved, partly because measuring demand is hard